Issue of Equity

RNS Number : 8242T
Avacta Group PLC
23 July 2015
 



 

23 July 2015


Avacta Group plc

("Avacta", the "Company" or the "Group")

 

Issue of Equity

 

Avacta Group plc (AIM: AVCT), the global provider of proprietary diagnostic tools, consumables and reagents for life sciences, today announces that 250,000 Ordinary Shares of 0.1p ("new Ordinary Shares") have been issued by the Company pursuant to the exercise of share options by an employee.

 

Application will be made for the new Ordinary Shares to be admitted to trading on AIM and dealings are expected to commence on 28 July 2015.

 

The total number of Ordinary Shares in issue following the above issue will be 4,979,649,550 each with voting rights.  No Ordinary Shares are held in Treasury.

 

The above figure of 4,979,649,550 shares may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FSA's Disclosure and Transparency Rules.

 

 

- Ends -

 

For further information:

 

Avacta Group plc

Alastair Smith, Chief Executive Officer

Tim Sykes, Chief Financial Officer

Tel:  +44 (0) 844 414 0452

www.avacta.com

 

Numis Securities Limited    

Michael Meade / Freddie Barnfield - Nominated Adviser

James Black - Corporate Broking

 

Tel:  +44 (0) 207 260 1000

www.numiscorp.com

 

Media Enquiries

FTI Consulting

Simon Conway / Natalie Garland-Collins

 

Tel: +44 (0) 20 3727 1000

avacta@fticonsulting.com

 

About Avacta Group plc - www.avacta.com

 

Avacta Group plc is a global provider of innovative technologies, consumables and reagents for the life science markets, from drug discovery to diagnostics. Avacta operates through two divisions:

 

 

Avacta Animal Health

www.avactaanimalhealth.com

 

Veterinary diagnostics reference laboratory and diagnostic kit provider.

 

Avacta Life Sciences

www.avactalifesciences.com

 

 

Novel non-antibody affinity reagents called Affimers, with a wide range of Life Science applications in diagnostics, drug and biomarker discover and biotech research and development.

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IOEUUONRVUABUAR
UK 100